Click here to sign in with or
Forget Password?
Learn more
share this!
Share
7
Share
Email
November 9, 2022
by Technical University Munich
In Alzheimer’s disease, the degeneration of brain cells is linked to formation of toxic protein aggregates and deposits known as amyloid plaques. Similar processes also play an important role in type 2 diabetes. A research team under the lead of the Technical University of Munich has now developed “mini-proteins,” so-called peptides, which are able to bind the proteins that form amyloids and prevent their aggregation into cytotoxic amyloids.
Many cell and neurodegenerative diseases are linked to the formation of toxic protein aggregates which cause cell death. Prominent representatives of these diseases are Alzheimer’s disease and type 2 diabetes mellitus, with worldwide more than 50 million and 400 million patients, respectively. Importantly, the number of Alzheimer’s and diabetes patients continues to rise, as the population becomes older. However, the two diseases remain so far incurable. Therefore, there is an urgent need for new therapeutic approaches.
Targeting the formation of harmful amyloid aggregates is a promising approach. A team led by Aphrodite Kapurniotu, a professor for Peptide Biochemistry at the Technical University of Munich (TUM), has now developed novel synthetic peptides, which are able in experimental models to block toxic amyloid aggregation linked to both diseases. Their research is published in Nature Communications.
Molecular interactions between Alzheimer’s disease and type 2 diabetes
Previous studies showed that certain “cross-interactions” between the amyloidogenic proteins of the two diseases dramatically accelerate their amyloid aggregation process. These findings could possibly explain why people suffering from one of the two diseases might have an increased risk for the other disease as well.
The team developed synthetic peptides that could function as effective inhibitors of amyloid aggregation in both diseases. Prof. Kapurniotu says, “The designed peptides are in fact able to bind the amyloidogenic proteins linked to both diseases and to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions. Remarkably, although the mixed aggregates formed by interactions of the designed peptides with the amyloidogenic proteins look very similar to harmful amyloid aggregates, they are completely devoid of cytotoxic effects. Moreover, these amyloid-resembling mixed aggregates become more efficiently taken up by the phagocytic immune cells than amyloid aggregates.”
Future studies to pave the way for medical application
Increasing evidence suggests that Alzheimer’s disease and type 2 diabetes are linked to each other. Prof. Kapurniotu believes thus that the designed peptides could be valuable candidates for the development of drugs for treating both diseases.
A patent application has been already filed by TUM. Additional studies are now planned to translate the findings from the experimental models into the clinic.
Explore further
Facebook
Twitter
Email
Feedback to editors
41 minutes ago
0
23 hours ago
0
Nov 07, 2022
0
Nov 04, 2022
0
Nov 04, 2022
0
1 minute ago
3 minutes ago
25 minutes ago
41 minutes ago
1 hour ago
5 hours ago
17 hours ago
17 hours ago
17 hours ago
17 hours ago
Aug 08, 2018
Jun 28, 2021
May 01, 2020
May 26, 2021
Jun 16, 2022
Jan 02, 2019
25 minutes ago
23 hours ago
20 hours ago
Nov 07, 2022
Nov 07, 2022
Nov 07, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.